Applications for San Francisco (Batch 12) extended AGAIN through September 30th, 2021!

Learn more about investing in Diadem Biotherapeutics

Our team will get back to you soon to follow up on your inquiry.
Diadem Biotherapeutics
Engineering the best receptor agonists
* Data source: Crunchbase
Founded
2019
Employees*
1-10
Funding to Date*
undisclosed
Website
diadembio.com
Dr. Mickey Pentecost, CEO
Because exosomes are remarkably robust entities, we're looking at various delivery formats including inhalable
Exosome therapeutic delivery market is expected to reach $30B by 2026, by a 22% CAGR

One way cells communicate to each other through long distances is via exosomes. Originally thought to be cellular garbage, exosomes are now a powerful opportunity for therapeutics. Many competitors are focused on packaging inside the exosome to use as delivery vesicles, and thus completely ignores the shell as a modality for therapeutics.

Diadem Biotherapeutics is engineering a platform to decorate the outside of exosomes, so that they act as signaling molecules. By engineering the surface of exosomes, with signaling agonists, they can craete a new therapeutic modality, 10,000X more potent than the unattached protein. Moreover, they can engineer potent combinations of multiple receptor agonists. The team is currently performing IND-enabling studies for oncology and autoimmune disorders.